These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 15823076)

  • 1. A word of caution on the use of high-dose MR contrast media in patients with renal failure.
    Geckeis K; Eggebrecht H; Quick HH; Barkhausen J; Kribben A; Erbel R
    J Endovasc Ther; 2005 Apr; 12(2):262. PubMed ID: 15823076
    [No Abstract]   [Full Text] [Related]  

  • 2. Gadolinium-based contrast media for multi-detector row spiral CT pulmonary angiography in patients with renal insufficiency.
    Morcos SK; Remy-Jardin M
    Radiology; 2006 Mar; 238(3):1077; author reply 1077-8. PubMed ID: 16505405
    [No Abstract]   [Full Text] [Related]  

  • 3. Seizure after gadolinium administration.
    Hailemeskal B; Ilogu E; Khuc K; Curry C; Kelvas M
    Radiol Technol; 1999; 70(4):387. PubMed ID: 10101755
    [No Abstract]   [Full Text] [Related]  

  • 4. Response.
    Davenport MS; Liu PS; Chenevert TL; Hussain HK
    Radiology; 2013 Sep; 268(3):927. PubMed ID: 24137709
    [No Abstract]   [Full Text] [Related]  

  • 5. [Nephrotoxicity of contrast media in magnetic resonance tomography (MRI)].
    Heuck A; Reiser M
    Internist (Berl); 1997 Dec; 38(12):1234-5. PubMed ID: 9465330
    [No Abstract]   [Full Text] [Related]  

  • 6. [Using low osmolar gadolinium for angiographic imaging and in interventional radiologic procedures in patients with renal failure].
    Strunk H
    Rofo; 2003 Apr; 175(4):571; author reply 571-2. PubMed ID: 12741405
    [No Abstract]   [Full Text] [Related]  

  • 7. Enhanced computed tomography or magnetic resonance imaging: a choice between contrast medium-induced nephropathy and nephrogenic systemic fibrosis?
    Thomsen HS; Marckmann P; Logager VB
    Acta Radiol; 2007 Jul; 48(6):593-6. PubMed ID: 17611863
    [No Abstract]   [Full Text] [Related]  

  • 8. [The Grenelle of MR contrast agents?].
    Clément O
    J Radiol; 2007 Nov; 88(11 Pt 1):1663. PubMed ID: 18065924
    [No Abstract]   [Full Text] [Related]  

  • 9. Does intravenous administration of gadoxetate disodium have any effect on breath-hold times.
    Bergmann K; Agris J; Balzer T
    Radiology; 2013 Sep; 268(3):926-7. PubMed ID: 23970514
    [No Abstract]   [Full Text] [Related]  

  • 10. Gadodiamide-based coronary angiography in a patient with severe renal insufficiency.
    Gupta R; Uretsky BF
    J Interv Cardiol; 2005 Oct; 18(5):379-83. PubMed ID: 16202115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of serial monthly administration of triple-dose gadopentetate dimeglumine in multiple sclerosis patients: preliminary results of the BECOME trial.
    Wolansky LJ; Haghighi MH; Sevdalis E; Cook SD; Sethi N; Liu J; Joseph G; Tulloch K; Cadavid D
    J Neuroimaging; 2005 Jul; 15(3):289-90. PubMed ID: 15951416
    [No Abstract]   [Full Text] [Related]  

  • 12. Inadvertent intraosseous gadolinium injection during pediatric shoulder MR arthrography.
    Pack JR; Jordanov MI; Block JJ
    Pediatr Radiol; 2008 Jul; 38(7):772-5. PubMed ID: 18414840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are patients with moderate renal failure at risk for developing nephrogenic systemic fibrosis?
    Saab G; Abu-Alfa A
    Radiology; 2007 Sep; 244(3):930-1; author reply 931-2. PubMed ID: 17709844
    [No Abstract]   [Full Text] [Related]  

  • 14. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.
    Wiginton CD; Kelly B; Oto A; Jesse M; Aristimuno P; Ernst R; Chaljub G
    AJR Am J Roentgenol; 2008 Apr; 190(4):1060-8. PubMed ID: 18356456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and effectiveness of single- versus triple-dose gadodiamide injection- enhanced MR angiography of the abdomen: a phase III double-blind multicenter study.
    Thurnher SA; Capelastegui A; Del Olmo FH; Dondelinger RF; Gervás C; Jassoy AG; Keto P; Loewe C; Ludman CN; Marti-Bonmati L; Meusel M; da Cruz JP; Pruvo JP; Sanjuan VM; Vogl T
    Radiology; 2001 Apr; 219(1):137-46. PubMed ID: 11274548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to the FDA's May 23, 2007, nephrogenic systemic fibrosis update.
    Kanal E; Broome DR; Martin DR; Thomsen HS
    Radiology; 2008 Jan; 246(1):11-4. PubMed ID: 17855656
    [No Abstract]   [Full Text] [Related]  

  • 17. Nephrogenic systemic fibrosis: possible association with a predisposing infection.
    Golding LP; Provenzale JM
    AJR Am J Roentgenol; 2008 Apr; 190(4):1069-75. PubMed ID: 18356457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contrast agent approved for liver imaging.
    Thompson CA
    Am J Health Syst Pharm; 2008 Aug; 65(16):1490. PubMed ID: 18693195
    [No Abstract]   [Full Text] [Related]  

  • 19. Extracellular Gd-CA: differences in prevalence of NSF.
    Thomsen HS; Marckmann P
    Eur J Radiol; 2008 May; 66(2):180-3. PubMed ID: 18342468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Eovist in Pediatric Patients: Pearls and Pitfalls.
    Shet NS; Flynn JF; Maloney E; Iyer RS
    Curr Probl Diagn Radiol; 2020; 49(4):266-274. PubMed ID: 31047739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.